This study evaluated the safety and immunogenicity of 3 formulations of Hib-MenCY-TT vaccine compared to 2 control groups receiving licensed meningococcal serogroup C conjugate vaccine and/or licensed Hib conjugate vaccine administered at 2, 4, and 6 months of age. Antibody persistence and immune responses to polysaccharide vaccine boosters were additionally assessed at 11 to 14 months of age.
Primary Outcome Measures:
- Evaluate antibody responses to Hib and meningococcal serogroups C an Y in 3 different Hib-MenCY-TT formulations as compared to licensed Hib and meningococcal serogroup C conjugate vaccines
Secondary Outcome Measures:
- Evaluate the safety and reactogenicity of the 3 Hib-MenCY-TT formulations
- Evaluate antibody persistence and immune memory induced by Hib-MenCY-TT
- Evaluate immune responses to co-administered Diptheria, Tetanus and Pertussis-Inactivated Polio Vaccine-Hepatitis B (DTaP-IPV-HepB) and 7-valent pneumococcal vaccines
Estimated Enrollment: |
400 |
Study Start Date: |
March 2003 |
Evaluate immuno. (incl. immune memory),reacto & safety of 3 diff. formul. of GSKBio combined Haemophilus influenzae typeb-meningococcal serogroups CY conjugate vaccine given concomitantly with Infanrix®penta DTaP-IPV-HepB vaccine) & Prevenar® (7-valent pneumo. vaccine) vs ActHIB® (Hibvaccine) & Meningitec® (meningococcal serogroupC vaccine) given concomitantly with Infanrix®penta (DTaP-IPV-HepB vaccine) & Prevenar® (7-valent pneumococcal vaccine)in infants according to a 2-4-6 mth schedule